Cargando…

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

BACKGROUND: Esaxerenone has potential renoprotective effects and reduces the urinary albumin-to-creatinine ratio (UACR) in patients with diabetic kidney disease and overt nephropathy. We investigated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes (T2D) and macroalbu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Sadayoshi, Kashihara, Naoki, Shikata, Kenichi, Nangaku, Masaomi, Wada, Takashi, Okuda, Yasuyuki, Sawanobori, Tomoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421271/ https://www.ncbi.nlm.nih.gov/pubmed/34110524 http://dx.doi.org/10.1007/s10157-021-02075-y

Ejemplares similares

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies
por: Shikata, Kenichi, et al.
Publicado: (2022)

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial
por: Okuda, Yasuyuki, et al.
Publicado: (2022)

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies
por: Ito, Sadayoshi, et al.
Publicado: (2023)

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
por: Kario, Kazuomi, et al.
Publicado: (2021)

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
por: Itoh, Hiroshi, et al.
Publicado: (2019)

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2019)

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
por: Arai, Kiyoshi, et al.
Publicado: (2020)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study
por: Kanda, Eiichiro, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Observation period for changes in proteinuria and risk prediction of end‐stage renal disease in general population
por: Usui, Tomoko, et al.
Publicado: (2018)

New measures against chronic kidney diseases in Japan since 2018
por: Fukui, Akira, et al.
Publicado: (2019)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease
por: Kume, Shinji, et al.
Publicado: (2018)

Macroalbuminuria and Renal Pathology in First Nation Youth With Type 2 Diabetes
por: Sellers, Elizabeth A.C., et al.
Publicado: (2009)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)

Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study
por: Iwahana, Togo, et al.
Publicado: (2021)

Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
por: Kurata, Akifumi, et al.
Publicado: (2019)

Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects
por: Lopes-Virella, Maria F., et al.
Publicado: (2013)

Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria
por: Krolewski, Andrzej S., et al.
Publicado: (2014)

Elevated Systemic Neutrophil Count Is Associated with Diabetic Macroalbuminuria among Elderly Chinese
por: Yang, Min, et al.
Publicado: (2015)

Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single‐Dose Crossover Studies in Healthy Japanese Men
por: Kurata, Akifumi, et al.
Publicado: (2022)

Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities
por: Sugawara, Yuka, et al.
Publicado: (2021)

A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity
por: Okamura, Keisuke, et al.
Publicado: (2020)

A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal Function Decline in Japanese Type 2 Diabetic Patients: Japan Diabetes Complications Study
por: Moriya, Tatsumi, et al.
Publicado: (2013)

A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues
por: Wada, Takehiko, et al.
Publicado: (2015)

Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study
por: Chida, Shoma, et al.
Publicado: (2016)

MiR-3150b inhibits hepatocellular carcinoma cell proliferation, migration and invasion by targeting GOLPH3
por: Zhang, Yi, et al.
Publicado: (2020)

Body Weight Control by a High-Carbohydrate/Low-Fat Diet Slows the Progression of Diabetic Kidney Damage in an Obese, Hypertensive, Type 2 Diabetic Rat Model
por: Ohtomo, Shuichi, et al.
Publicado: (2010)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome
por: Fujisawa, Madoka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hj4qubjvkegmp1otkg7eknddga